Abstract:
The invention relates to novel ionic liquids and to the production and use thereof. The novel ionic liquids are salts of sulphonated or carboxylated triesters of phosphorous acid as the anionic component and ammonium ions, which can be substituted with organic radicals, as the cationic component.
Abstract:
The invention relates to inhibitors of sphingosine kinase enzymatic activity, compounds and pharmaceutical compositions that inhibit sphingosine kinase 1 and sphingosine kinase 2 (SphK1 & SphK2) enzymes and further relates to methods of treating diseases and disorders mediated by sphingosine 1 phosphate activity, comprising administering an effective amount of sphingosine kinase inhibitors.
Abstract:
The invention provides a cationic lipid comprising: (i) one head group, comprising one or more amino acids, in which at least one amino acid has a side chain that comprises a cationic moiety or a cationic precursor; a linking moiety of formula (5): -(HNR 5 ) 2 NC(0)R 3 C(0)- (5), wherein: each R 5 is independently an optionally substituted alkylene moiety; and R 3 is an optionally substituted alkylene or alkenylene moiety; and (iii) two lipophilic moieties, wherein the head group and each of the lipophilic moieties are connected to the linking moiety through amide linkages.
Abstract:
The invention relates to inhibitors of sphingosine kinase enzymatic activity, compounds and pharmaceutical compositions that inhibit sphingosine kinase 1 and sphingosine kinase 2 (SphK1 & SphK2) enzymes and further relates to methods of treating diseases and disorders mediated by sphingosine 1 phosphate activity, comprising administering an effective amount of sphingosine kinase inhibitors.
Abstract:
Provided are methods of preparing polymers, such as polyisoprene, polybutadiene, polypiperylene, polycyclohexadiene, poly-ß-farnesene, or poly-ß-myrcene, using iron complexes. Also provided are novel iron complexes, pre-catalysts, intermediates, and ligands useful in the inventive polymerization system.
Abstract:
Provided are methods of preparing polymers, such as polyisoprene, polybutadiene, polypiperylene, polycyclohexadiene, poly-β-farnesene, or poly-β-myrcene, using iron complexes. Also provided are novel iron complexes, pre-catalysts, intermediates, and ligands useful in the inventive polymerization system.
Abstract:
The invention concerns compounds inhibiting LTA4 hydrolase of formula (I). The invention also concerns their therapeutic, in particular anti-inflammatory, applications.